Please ensure Javascript is enabled for purposes of website accessibility

Vertex Pharmaceuticals Raises Bet on CRISPR Therapeutics

By Cory Renauer - Updated Apr 20, 2021 at 4:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The amended collaboration agreement comes with a big up-front payment.

The relationship between Vertex Pharmaceuticals (VRTX -1.02%) and CRISPR Therapeutics (CRSP 4.98%) is taking another big step forward. On Tuesday morning, the collaboration partners amended their agreement regarding CTX001 in a way that places more risk on Vertex's shoulders.

CRISPR Therapeutics and Vertex had already agreed to co-commercialize and co-develop CTX001, an experimental gene therapy for patients with sickle cell disease (SCD) or transfusion-dependent beta-thalassemia (TDT). This new amendment raises Vertex's share of development expenses and potential profits to 60% while lowering CRISPR Therapeutics' share to 40% in return for a big up-front sum.

Scientist at work.

Image source: Getty Images.

If the experimental gene therapy earns approval to treat severe sickle cell disease (SCD) or transfusion-dependent beta-thalassemia (TDT), CRISPR Therapeutics could receive a $200 million milestone payment.  

CRISPER Therapeutics wasn't starved for cash going into this amendment, but it could be a long time before the company has any approved products to sell. CTX001 uses a patient's own stem cells after they've been engineered to produce high levels of functional hemoglobin.

The SCD and TDT patients treated in clinical trials relied heavily on blood transfusions before receiving CTX001. So far, the treatment appears capable of eliminating their reliance on transfusions for at least a few years following a single administration.

Unfortunately, just a few patients have long-term data, so it's going to be years before we can expect steady revenue from CTX001. In the meantime, CRISPR Therapeutics has a great big cash cushion to rest on.

When the deal completes, CRISPR Therapeutics will add the $900 million up-front payment to a balance sheet that finished 2020 with $1.7 billion in cash. This gives the company more than two years to develop its early clinical-stage cancer therapies before it needs to ask investors for more capital.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends CRISPR Therapeutics. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
$78.87 (4.98%) $3.74
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$295.77 (-1.02%) $-3.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.